Back to Search
Start Over
1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
- Source :
- Annals of Oncology. 32:S931
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
Details
- ISSN :
- 09237534
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........7e9688b78de4bfcbac238a3f56cf7839